|
ADVANCED-J
Amlodipine Versus Angiotensin II receptor blocker: Control of blood pressure Evaluation trial in Diabetics – Japan
Ongoing trial
 |
Author(s) |
Kawamori R, Daida H, Tanaka Y, Miyauchi K, Kitagawa A, Hayashi D, Kishimoto J, Ikeda S, Imai Y, Yamazaki T |
 |
Title(s) |
Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J) |
|
Reference(s) |
BMC Cardiovasc Disord 2006;6:39 |
|
Disease |
Diabetes mellitus, hypertension |
|
Purpose |
To compare the effects on morning home BP of increasing the dose of an angiotensin-receptor blocker vs adding amlodipine to the treatment in patients with diabetes and hypertension whose BP was inadequately controlled by the angiotensin-receptor blocker |
|
Study design |
Randomised, open |
|
Follow-up |
Aim 3 years |
|
Patients |
Aim 300 patients, aged ≥ 20 years, with type 2 diabetes, sitting office BP between 135/85 and 180/110 mm Hg and morning home BP > 130/80 mm Hg, taking an angiotensin-receptor blocker with or without an antihypertensive drug other than calcium antagonists and ACE inhibitors for at least 8 weeks |
|
Treatment regimen |
Maximum dose approved of one angiotensin-receptor blocker (candesartan cilexetil, 12 mg/day, losartan, 100 mg/day, olmesartan, 40 mg/day, telmisartan, 80 mg/day, or valsartan, 160 mg/day) or amlodipine, 5 mg/day, plus one angiotensin-receptor blocker (candesartan cilexetil, 8 mg/day, losartan, 50 mg/day, olmesartan, 20 mg/day, telmisartan, 40 mg/day, or valsartan, 80 mg/day) |
|
Concomitant therapy |
Other antihypertensive drugs except calcium antagonists and ACE inhibitors (dose increase group) or angiotensin-receptor blockers and ACE inhibitors (amlodipine group) at the discretion of the physician |
|
Results |
Not yet available |
|
Comments |
Data on the correlation between nephropathy and morning home BP or office BP in the ADVANCED-J patient population have been published in Hypertens Res 2009;32:770–4 |
|
|
|
